United States Patent [19]

Kludas

[11] **Patent Number: 5,036,056**

[45] **Date of Patent: Jul. 30, 1991**

[54] **METHODS FOR TREATING DAMAGED CORNEAL, UTERINE, OR CARTILAGE TISSUE**

[76] Inventor: **Martin Kludas**, Herthastrasse 22, D-1000 West Berlin-33, Fed. Rep. of Germany

[21] Appl. No.: **500,330**

[22] Filed: **Mar. 27, 1990**

Related U.S. Application Data

[63] Continuation of Ser. No. 70,991, Jul. 8, 1987, abandoned.

[51] **Int. Cl.**[5] **A61K 31/715**; C07H 5/04

[52] **U.S. Cl.** **514/54**; 514/912; 514/935; 536/55.1; 536/55.2

[58] **Field of Search** 536/55.1, 55.2; 514/54, 514/912, 935; 424/59

[56] **References Cited**

U.S. PATENT DOCUMENTS

Re. 30,239	3/1980	Kuettner et al.	424/569
3,839,590	10/1974	Battista	514/773
3,887,703	6/1975	Manoussos	424/581
3,991,184	11/1976	Kludas et al.	514/21
4,042,457	8/1977	Kuettner et al.	424/548
4,108,849	8/1978	Thomas	530/395
4,228,153	10/1980	Burov et al.	514/774
4,296,099	10/1981	Berrebi et al.	424/582
4,327,078	4/1982	Charlet et al.	424/45
4,389,487	6/1983	Ries	435/273
4,420,339	12/1983	Kato	106/124
4,448,718	5/1984	Yannas et al.	530/356
4,451,397	5/1984	Huc et al.	530/356
4,464,362	8/1984	Kludas et al.	424/114
4,488,911	12/1984	Luck et al.	106/161
4,511,653	4/1985	Play et al.	435/68.1
4,642,292	2/1987	Reid et al.	435/240
4,664,110	5/1987	Schanzlin	606/20
4,696,813	9/1987	Higa	424/59

FOREIGN PATENT DOCUMENTS

128706A3	12/1984	European Pat. Off. .
154447A2	9/1985	European Pat. Off. .
1730	3/1963	France .
6652	1/1969	France .
2299019	8/1976	France .
2487197	1/1982	France .
2591107	6/1987	France .
1386864	2/1972	United Kingdom .

Primary Examiner—Catherine S. Kilby Scalzo
Attorney, Agent, or Firm—Pennie & Edmonds

[57] **ABSTRACT**

Methods for treating damaged corneal, uterine or cartilage tissue comprising applying a therapeutically effective amount of a composition comprising:

(a) a sterile extracellular connective tissue matrix composition comprising collagens, proteoglycans, glycosaminoglycans and glycoproteins wherein said collagens, said proteoglycans, said glycosamino glycans, and said glycoproteins have each been extracted from an extracellular connective tissue matrix and are in their native structural form and

(b) a pharmaceutically acceptable carrier.

31 Claims, No Drawings